Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03382613 · ClinicalTrials.gov registry record
A Study to Quantify Use of Anticoagulation to Improve Management of Atrial Fibrillation
A clinical trial, sponsored by Janssen Scientific Affairs.
- Terminated
- Registry status
- 2,000
- Enrollment target
NCT03382613 is a clinical trial that was terminated before completion, run by Janssen Scientific Affairs. The registered enrollment target is 2,000 participants.
The verdict
NCT03382613 was terminated before completion, sponsored by Janssen Scientific Affairs.
- TERMINATED
- Registry status
- 2,000 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the impact of a hospital quality improvement (QI) program on the use of guideline-recommended oral anticoagulants (OAC) in hospitalized patients with atrial fibrillation (AF) at risk for ischemic stroke. Specifically, the study will determine whether the intervention, compared to Usual Care, will result in a greater increase in the proportion of patients with AF at risk for ischemic stroke who are appropriately treated with OAC.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2017-12-29 |
| Est. Completion | 2019-12-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03382613
The ClinicalTrials.gov registry entry for NCT03382613 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Scientific Affairs, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03382613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03382613 about?
NCT03382613 is a clinical study titled "A Study to Quantify Use of Anticoagulation to Improve Management of Atrial Fibrillation". The purpose of this study is to evaluate the impact of a hospital quality improvement (QI) program on the use of guideline-recommended oral anticoagulants (OAC) in hospitalized patients with atrial fibrillation (AF) at risk for ischemic stroke. Specifically, the study will determine whether the inte...
What is the current status of trial NCT03382613?
This trial is currently terminated. The enrollment target is 2,000 participants. The study started on 2017-12-29. Estimated completion is 2019-12-03.
Who is sponsoring clinical trial NCT03382613?
This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.